Arginase-1, HepPar-1, and glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens

American Journal of Clinical Pathology

Volumn 138, Issue 2, 2012, Pages 203-210

  Timek, Dana T ^a   Shi, Jianhui ^a   Liu, Haiyan ^a   Lin, Fan ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Arginase 1; Carcinomas; Cytology; Glypican 3; Hepatocellular carcinomas; HepPar 1

Indexed keywords

ARGINASE 1; BIOLOGICAL MARKER; GLYPICAN 3; HEPATOCYTE PARAFFIN 1; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION BIOPSY; CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADENOCARCINOMA; ARGINASE; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER DISEASES; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM GRADING; TUMOR MARKERS, BIOLOGICAL;

EID: 84865435615     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPK1ZC9WNHCCMU     Document Type: Article

References (35)

1. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002;26:978-988. (Pubitemid 34810558)
2. Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol. 1998;11:934-938. (Pubitemid 28487210)
3. Leong AS, Sormunen RT, Tsui WM, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998;33:318-324. (Pubitemid 28508880)
4. Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol. 2001;115:689-694. (Pubitemid 33051535)
5. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10:686-692. (Pubitemid 27321760)
6. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13:874-881. (Pubitemid 30643835)
7. Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009;34:649-656.
8. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132:1723-1728.
9. Wang L, Vuolo M, Suhrland MJ, et al. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol. 2006;50:257-262. (Pubitemid 43837037)
10. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol. 1993;143:1050-1054. (Pubitemid 24070547)
11. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575. (Pubitemid 44808793)
12. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230.
13. Anatelli F, Chuang ST, Yang XJ, et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008;130:219-223.
14. Ou-Yang RJ, Hui P, Yang XJ, et al. Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol. 2010;5:64.
15. Zhang L, Liu H, Sun L, et al. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study [published online ahead of print November 24]. Acta Histochem. 2011.
16. Lugli A, Tornillo L, Mirlacher M, et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004;122:721-727. (Pubitemid 39434753)
17. Fan Z, van de Rijn M, Montgomery K, et al. Hep Par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144. (Pubitemid 36245745)
18. Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican-3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008;129:899-906.
19. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer Cytopathol. 2007;111:316-322.
20. Saad RS, Luckasevic TM, Noga CM, et al. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol. 2004;30:1-6. (Pubitemid 38040672)
21. Wee A. Fine needle aspiration biopsy of the liver: algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma. Cytojournal. 2005;2:7.
22. Wee A. Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. Pathol Res Int 2011;2011:587936.
23. Wee A. Fine-needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology. 2011;22:287-305.
24. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147-1154.
25. Taylor SL, Haque S. Hepatobiliary pathology. Curr Opin Gastroenterol 2011;27:248-255.
26. Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 2007;31:371-381. (Pubitemid 46673110)
27. Wilkerson ML, Powell E. Tissue Microarray. In: Lin F, Prichard J, Liu H, et al. eds. Handbook of Practical Immunohistochemistry: Frequently Asked Questions New York, NY: Springer; 2011:45-54.
28. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma - with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78-91.
29. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a diagnostic marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129:592-605. (Pubitemid 352029279)
30. Ishak KG, Goodman ZD, Stocker JT. Tumor of the liver and intrahepatic bile ducts: In: Atlas of Tumor Pathology, Third Series, Fascicle 31. Washington, DC: Armed Forces Institute of Pathology; 2001:9-48.
31. .Liu H, Shi J, Wilkerson M, et al. Immunohistochemical detection of p16INKa in liquid-based cytology specimens on cell block sections. Cancer. 2007;111:74-82. (Pubitemid 46648405)
32. Kakar S, Muir T, Murphy LM, et al. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol. 2003;119:361-366. (Pubitemid 37047858)
33. Kakar S, Gown AM, Goodman ZD, et al. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131:1648-1654. (Pubitemid 350077461)
34. Yim SH, Chung YJ. An overview of biomarkers and molecular signatures in HCC. Cancers. 2010;2:809-823.
35. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011-1018.